Abnormal inflammation leads to maternal coagulopathies associated with placental haemostatic alterations in a rat model of foetal loss

Summary

Spontaneous pregnancy loss is often associated with aberrant maternal inflammation and systemic coagulopathies. However, the role of inflammation in the development of obstetric coagulopathies is poorly understood. Further, questions remain as to whether systemic coagulo-pathies are linked to placental haemostatic alterations, and whether these local alterations contribute to a negative foetal outcome. Using a model of spontaneous foetal loss in which pregnant rats are given a single injection of bacterial lipopolysaccharide (LPS), we characterised the systemic maternal coagulation status following LPS administration using thromboelastography (TEG), a global haemostatic assay that measures the kinetics of clot formation. Systemic maternal coagulopathy was evident in 82% of LPS-treated rats. Specifically, we observed stage-I, -II, and -III disseminated intravascular coagulation (DIC) and hypercoagulability. Modulation of inflammation through inhibition of tumour necrosis factor α with etanercept resulted in a 62% reduction in the proportion of rats exhibiting coagulopathy. Moreover, inflammation-induced systemic coagulopathies were associated with placental haemostatic alterations, which included increased intravascular, decidual, and labyrinth fibrin deposition in cases of DIC-I and hypercoagulability, and an almost complete absence of fibrin deposition in cases of DIC-III. Furthermore, systemic and placental haemostatic alterations were associated with impaired utero-placental haemodynamics, and inhibition of these haemostatic alterations by etanercept was associated with maintenance of utero-placental haemodynamics. These findings indicate that modulation of maternal inflammation may be useful in the prevention of coagulopathies associated with complications of pregnancy.

Keywords

Pregnancy loss - coagulopathy - inflammation - rat - haemodynamics

• References

• 1 Brenner B. Hypercoagulability and recurrent miscarriages. Clin Adv Hematol Oncol 2010; 08: 467-469.
• 2 Sarig G, Younis JS, Hoffman R. et al. Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril 2002; 77: 342-347.
• 3 Kwak-Kim J, Park JC, Ahn HK. et al. Immunological modes of pregnancy loss. Am J Reprod Immunol 2010; 63: 611-623.
• 4 Kwak-Kim J, Yang KM, Gilman-Sachs A. Recurrent pregnancy loss: a disease of inflammation and coagulation. J Obstet Gynaecol Res 2009; 35: 609-622.
• 5 Laskin CA, Chuma A, Angelov L. et al. Sera from habitual aborters induce mono-cyte procoagulant activity: a lymphocyte-dependent event. Clin Immunol Immu-nopathol 1994; 73: 235-244.
• 6 Babbage SJ, Arkwright PD, Vince GS. et al. Cytokine promoter gene polymorphisms and idiopathic recurrent pregnancy loss. J Reprod Immunol 2001; 51: 21-27.
• 7 Ng SC, Gilman-Sachs A, Thaker P. et al. Expression of intracellular Th1 and Th2 cytokines in women with recurrent spontaneous abortion, implantation failures after IVF/ET or normal pregnancy. Am J Reprod Immunol 2002; 48: 77-86.
• 8 Raghupathy R. Th1-type immunity is incompatible with successful pregnancy. Immunol Today 1997; 18: 478-482.
• 9 Raghupathy R, Makhseed M, Azizieh F. et al. Maternal Th1- and Th2-type reactivity to placental antigens in normal human pregnancy and unexplained recurrent spontaneous abortions. Cell Immunol 1999; 196: 122-130.
• 10 Berman J, Girardi G, Salmon JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005; 174: 485-490.
• 11 Silver RM, Lohner WS, Daynes RA. et al. Lipopolysaccharide-induced fetal death: the role of tumor-necrosis factor alpha. Biol Reprod 1994; 50: 1108-1112.
• 12 Renaud SJ, Cotechini T, Quirt JS. et al. Spontaneous pregnancy loss mediated by abnormal maternal inflammation in rats is linked to deficient uteroplacental per-fusion. J Immunol 2011; 186: 1799-1808.
• 13 Brenner B, Aharon A. Thrombophilia and adverse pregnancy outcome. Clin Peri-natol 2007; 34: 527-541. v
• 14 Benedetto C, Marozio L, Tavella AM. et al. Coagulation disorders in pregnancy: acquired and inherited thrombophilias. Ann NY Acad Sci 2010; 1205: 106-117.
• 15 Carp HJ. Thrombophilia and recurrent pregnancy loss. Obstet Gynecol Clin North Am 2006; 33: 429-442.
• 16 De Wolf F, Carreras LO, Moerman P. et al. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol 1982; 142: 829-834.
• 17 Kramer MS, Usher RH, Pollack R. et al. Etiologic determinants of abruptio placentae. Obstet Gynecol 1997; 89: 221-226.
• 18 Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008; 08: 776-787.
• 19 Thachil J, To h CH. Disseminated intravascular coagulation in obstetric disorders and its acute haematological management. Blood Rev 2009; 23: 167-176.
• 20 Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-592.
• 21 Vincent T, Rai R, Regan L. et al. Increased thrombin generation in women with recurrent miscarriage. Lancet 1998; 352: 116.
• 22 Woodhams BJ, Candotti G, Shaw R. et al. Changes in coagulation and fibrinoly-sis during pregnancy: evidence of activation of coagulation preceding spontaneous abortion. Thromb Res 1989; 55: 99-107.
• 23 Othman M, Powell S, Chirinian Y. et al. Thromboelastography reflects global he-mostatic variation among severe haemophilia A dogs at rest and following acute exercise. Haemophilia 2009; 15: 1126-1134.
• 24 Filler SG, Solis NV, Guo J. et al. Pharmacokinetics of murine p75-Fc fusion protein and MP6-XT22 anti-murine TNF-alpha mAb in mice. J Investig Dermatol Symp Proc 2007; 12: 52-56.
• 25 Brenner B, Sarig G, Weiner Z. et al. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost 1999; 82: 6-9.
• 26 Stirling Y, Woolf L, North WR. et al. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52: 176-182.
• 27 Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003; 16: 153-168.
• 28 Fust G, Bertok L, Juhasz-Nagy S. Inter actions of radio-detoxified Escherichia coli endotoxin preparations with the complement system. Infect Immun 1977; 16: 26-31.
• 29 Kobayashi T, Sumimoto K, Tokunaga N. et al. Coagulation index to distinguish severe preeclampsia from normal pregnancy. Semin Thromb Hemost 2002; 28: 495-500.
• 30 Rousseau A, Favier R, Van Dreden P. Elevated circulating soluble thrombomodu-lin activity, tissue factor activity and circulating procoagulant phospholipids: new and useful markers for pre-eclampsia?. Eur J Obstet Gynecol Reprod Biol 2009; 146: 46-49.
• 31 Asakura H, Suga Y, Aoshima K. et al. Marked difference in pathophysiology between tissue factor- and lipopolysaccharide-induced disseminated intravascular coagulation models in rats. Crit Care Med 2002; 30: 161-164.
• 32 Orlikowski CE, Rocke DA, Murray WB. et al. Thrombelastogr aphy changes in pre-eclampsia and eclampsia. Br J Anaesth 1996; 77: 157-161.
• 33 Dossenbach-Glaninger A, van Trotsenburg M, Krugluger W. et al. Elevated coagulation factor VIII and the risk for recurrent early pregnancy loss. Thromb Hae-most 2004; 91: 694-699.
• 34 Iwaki T, Castellino FJ. Maternal fibrinogen is necessary for embryonic development. Curr Drug Targets 2005; 06: 535-539.
• 35 Rey E, Kahn SR, David M. et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 901-908.